{
    "nct_id": "NCT05039177",
    "official_title": "A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)",
    "inclusion_criteria": "* Age ≥ 18 years.\n* Willing and able to give written informed consent.\n* Have histologically or cytologically confirmed metastatic CRC harboring applicable mutation(s) (e.g., BRAF V600E; KRAS or NRAS mutations) or metastatic PDAC harboring KRAS mutation based on an analytically validated assay performed on tumor tissue in a certified testing laboratory.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Adequate bone marrow and organ function.\n* Have ECOG performance status of 0 or 1.\n* Willing to comply with all protocol-required visits, assessments, and procedures.\n* Able to swallow oral medication.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Prior therapy with a RAS, MEK, or ERK inhibitor. Depending on which treatment arm the patient is assigned, other therapies could also be prohibitive.\n* Anti-cancer therapy ≤ 21 days or 4 half-lives prior to first dose of study drug, whichever is shorter.\n* Palliative radiation ≤ 7 days prior to first dose of study drug.\n* Symptomatic brain metastasis or leptomeningeal disease.\n* Gastrointestinal conditions that may affect absorption of oral medications\n* Active infection requiring systemic therapy, or a known history of HIV infection, hepatitis B virus, or hepatitis C virus.\n* History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first study drug dose.\n* Active, clinically significant interstitial lung disease or pneumonitis.\n* Impaired cardiovascular function or clinically significant cardiovascular disease.\n* History of thromboembolic or cerebrovascular events ≤ 6 months prior to first dose.\n* Major surgery within 28 days of enrollment, or anticipation of major surgery during study treatment.\n* Known intolerance or contraindication to encorafenib, cetuximab, or palbociclib.\n* Pregnant or breastfeeding women.\n* Any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study.",
    "miscellaneous_criteria": ""
}